Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 7, 2022

Primary Completion Date

November 18, 2024

Study Completion Date

November 18, 2024

Conditions

Fibrous Dysplasia Of Bone

Interventions

DRUG

Burosumab

Human recombinant monoclonal antibody to fibroblast growth factor-23 (FGF23)

Trial Locations (1)

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Institute of Dental and Craniofacial Research (NIDCR)

NIH